Taken together, these findings suggest that severe disruptions to PTEN and TP53 function in untreated prostate tumors may be independently associated with elevated TGF-β activity and may serve as a genomic biomarker of tumors with propensity to resist RT and/or ADT. Here, TGFB1 is linked to prostate neoplasm.